Kerin N Z, Ansari-Leesar M, Faitel K, Narala C, Frumin H, Cohen A
Department of Medicine, Sinai Hospital, Detroit, MI 48235.
Am Heart J. 1993 Apr;125(4):1017-21. doi: 10.1016/0002-8703(93)90109-m.
The effectiveness and safety of quinidine in the conversion of chronic atrial fibrillation after administration of amiodarone was assessed in 15 patients. A total quinidine dosage of 1097 +/- 408 mg was administered up the point of conversion or for a total of 48 hours. Nine of 15 patients (60%) converted to sinus rhythm. No clinical variable such as the duration of atrial fibrillation, left atrial size, left ventricular fractional shortening, amiodarone duration, or maintenance dose of amiodarone was able to discriminate between converters and nonconverters when patients were treated with the combination of amiodarone and quinidine. The mean QT interval with amiodarone was 414 +/- 44 msec and slightly increased to 434 +/- 40 msec (p = 0.01) when quinidine was added. The amiodarone-quinidine combination was well tolerated, and no side effects or proarrhythmias were recorded.
对15例患者评估了奎尼丁在胺碘酮给药后转复慢性房颤的有效性和安全性。直至转复或总共48小时,共给予奎尼丁1097±408mg。15例患者中有9例(60%)转复为窦性心律。当患者接受胺碘酮和奎尼丁联合治疗时,房颤持续时间、左房大小、左室短轴缩短率、胺碘酮用药时间或胺碘酮维持剂量等临床变量均无法区分转复者和未转复者。使用胺碘酮时平均QT间期为414±44毫秒,加用奎尼丁后略有增加至434±40毫秒(p=0.01)。胺碘酮-奎尼丁联合用药耐受性良好,未记录到副作用或心律失常。